Biogen — how they publish

10 posts · curated by ViralLoop

80 posts from @biogen, Jun 2025 to Sep 2026: a typical post earns 4 likes. That is more than 38% of the 275 other S&P 500 companies we hold content for. About 1 in 4 of their posts opens with a number.

Biogen@biogen

#News: Today, we announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for an investigational therapy for spinal muscular atrophy (SMA). Learn more about this important milestone: t.co

Opens with an observation

Biogen@biogen

#News: We announced topline results from a Phase 2 study for an investigational drug targeting tau in individuals with early Alzheimer’s disease. These results represent an important milestone for the field. Learn more: t.co

Opens with an observation

Biogen@biogen

#News: We announced the completion of the acquisition of RayThera Inc. This acquisition marks another step in growing Biogen’s immunology portfolio, adding multiple potential assets for immune-mediated diseases. Read more: t.co

Opens with an observation

Biogen@biogen

#News: We’re attending the @alzassociation’s International Conference (#AAIC26) to share new data from our Alzheimer’s disease portfolio—including initial data from the Phase 2 study of our investigational tau-targeting therapy. Learn more: t.co

Opens with an observation

Biogen@biogen

#News: Today, we announced an agreement to acquire RayThera Inc. With this deal, we aim to add multiple immunology assets to our portfolio that will contribute to our long-term pipeline potential. Read more about this deal: t.co

Opens with an observation

Biogen@biogen

#News: With @ucb_news, we announced data at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, for an investigational therapy for systemic lupus erythematosus (SLE). Learn more about the data: t.co

Opens with an observation

Biogen@biogen

#News: Today, the FDA approved a new dosing regimen option for our spinal muscular atrophy (SMA) therapy. This approval represents an important step toward expanding options for people living with SMA. Learn more: t.co

Opens with an observation

Biogen@biogen

#News: Together with Eisai, we announced that the FDA has approved a new delivery option for people living with early Alzheimer’s disease. Learn more: t.co

Opens with an observation

Biogen@biogen

#News: Data from a Phase 2/3 study for SMA has been published in @NatureMedicine, exploring the potential benefit for a broad range of people living with the disease. Read more: t.co

Opens with an observation

Biogen@biogen

#News: Together with @StokeTx, we announced the first patient has been dosed in a Phase 3 study for our investigational therapy for Dravet syndrome. Read more: t.co

Opens with an observation